Double-Blind Clinical Trial of Arginine Supplementation in the Treatment of Adult Patients with Sickle Cell Anaemia

Table 1

Baseline characteristics of the patients.

	Placebo Group		Study Group		p-value
Gender (n/)					>0.99
Female	13	52,0%	13	52,0%
Male	12	48,0%	12	48,0%
Age (Years)	28		28		0.84
HU doses (mg/day)	1040		1070
Time of use of HU (months)
02 – 48	17	68,0%	14	56,0%	0.67
49 – 96	6	24,0%	8	32,0%
>97	2	8,0%	3	12,0%
Hospitalization (n/)
Never	9	36,0%	9	36,0%	0.91
5 years	3	12,0%	2	8,0%
3 years	6	24,0%	5	20,0%
This year	7	28,0%	9	36,0%
Vaso-occlusive crisis (n/)
No	5	23%	7	28%	0,74
Yes	20	77%	18	72%
Osteonecrosis (n/)
No	23	92%	23	92%	>0.99
Yes	2	8%	2	8%
Leg lesion (n/)
No	22	88%	24	96%	0.60
Yes	3	12%	1	4%

hi-square test. ^βFisher’s test. ^γMann-Whitney test. HU: hydroxyurea.